First Healthy Volunteer Dosed in Phase 1 Trial of RXC007 for IPF

First Healthy Volunteer Dosed in Phase 1 Trial of RXC007 for IPF

296231

First Healthy Volunteer Dosed in Phase 1 Trial of RXC007 for IPF

The first healthy volunteer has been dosed in a Phase 1 clinical evaluating RXC007, Redx Pharma’s investigational oral therapy for idiopathic pulmonary fibrosis (IPF) and other fibrotic, or scarring-related, conditions. “The start of our first clinical study with RXC007 is an important milestone for Redx,” Lisa Anson, Redx’s CEO, said in a press release. “We believe there is enormous potential for RXC007 to treat multiple fibrotic diseases and we will initially focus on idiopathic pulmonary fibrosis (IPF),…

You must be logged in to read/download the full post.